PT  - JOURNAL ARTICLE
AU  - Unlu, Eren
AU  - Léger, Hippolyte
AU  - Motornyi, Oleksandr
AU  - Rukubayihunga, Alia
AU  - Ishacian, Thibaud
AU  - Chouiten, Mehdi
TI  - Epidemic analysis of COVID-19 Outbreak and Counter-Measures in France
AID  - 10.1101/2020.04.27.20079962
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20079962
4099  - http://medrxiv.org/content/early/2020/05/01/2020.04.27.20079962.short
4100  - http://medrxiv.org/content/early/2020/05/01/2020.04.27.20079962.full
AB  - The COVID-19 pandemic has triggered world-wide attention among data scientists and epidemiologists to analyze and predict the outcomes, by using previous statistical epidemic models. We propose to use a variant of the well known SEIR model to analyze the spread of COVID-19 in France, by taking in to account the national lockdown declared in March 11, 2020. Particle Swarm Optimisation (PSO) is used to find optimal parameters for the model in the case of France. We propose to fit the model based only on the number of daily fatalities, where an R2 score based error metric is used. As the official number of confirmed cases is not reliable due to the lack of widespread testing, especially in the first phases of the outbreak, we show that basing the model optimisation on the number of fatalities can provide legitimate results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to coronavirus daily fatalities are taken from open sources. https://coronavirus.jhu.edu/